Author Archives: azaleaazelia

    Homologous (allogeneic) use: The repair, reconstruction, replacement, or supplementation of a recipient’s cells or tissues with a human cells, tissues, and cellular and tissue-based product that performs the same basic function or functions in the recipient as in … Continue reading →

  Delivery on the promise of cardiac regenerative therapy will require development of novel strategies leveraging knowledge gained in prior trials to prospectively identify patients likely to respond to therapy and optimize therapeutic potency through evidence-based cell characterization, preparation, and … Continue reading →

      The cardiAMP Heart Failure trial, a randomized, double-blind pivotal study enrolling patients with ischemic cardiomyopathy, left ventricle ejection fraction 20% to 40%, is the first to incorporate a cell potency score in screening criteria. In addition to … Continue reading →

  Prospective analysis of regenerative capacity These studies suggest that biomarkers and functional assays may be helpful to identify, a priori, cells and recipients with a higher capacity for tissue regeneration. But instead of retrospective identification of advantageous biomarker profiles, … Continue reading →

  Similarly, in the PERFECT trial (Intramyocardial Transplantation of Bone Marrow Stem Cells for Improvement of Post-Infarct Myocardial Regeneration in Addition to CABG Surgery), patients with ischemic cardiomyopathy received intramyocardial autologous CD133+bone marrow cells or placebo at coronary revascularization surgery. … Continue reading →

  Markers of intrinsic regenerative capacity Other studies suggest significant variation in intrinsic regenerative capacity, which could be useful to identify likely responders versus nonresponders. In FOCUS-CCTRN (First Mononuclear Cells Injected in the United States Study Conducted by the Cardiovascular … Continue reading →

  In LATE-TIME (Late Timing in Myocardial Infarction), patients with left ventricular (LV) ejection fraction ≤45% received intracoronary autologous bone marrow cells or placebo 2 to 3 weeks after reperfused ST-segment-elevation myocardial infarction. Although the overall results did not show … Continue reading →